LSU officials in high-level discussions about head coach Brian Kelly's future after a 49-25 loss to Texas A&M, with a buyout complicating any separation.
Novartis nears $12B acquisition of Avidity Biosciences, a biotech with a promising platform for delivering RNA therapeutics to muscle tissue.
LSU officials in high-level discussions about head coach Brian Kelly's future after a 49-25 loss to Texas A&M, with a buyout complicating any separation.
Novartis nears $12B acquisition of Avidity Biosciences, a biotech with a promising platform for delivering RNA therapeutics to muscle tissue.
